United Therapeutics Reports Early Success For External Liver Support In Acute Failure

United Therapeutics Corp. (NASDAQ:UTHR) on Monday shared results from its phase 1 study of miroliverELAP, an external liver assist product, in patients with acute forms of liver failure.

Developed by Miromatrix Medical, a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood circuit and a single-use bioengineered liver sustained outside of the human body to provide temporary liver support to patients.

The bioengineered liver is manufactured by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human liver cells isolated from donated human livers.

The donated human livers are not suitable for transplantation and are provided by organ procurement organizations.

Positive Phase 1 Results for MiroliverELAP

In the study, five patients with acute liver failure who were not candidates for a liver transplant were treated with miroliverELAP for at least 44 hours.

The treatment met its primary endpoint of survival during the study, with no unexpected serious adverse events reported over a subsequent 32-day follow-up period.

The positive results highlight the potential of miroliverELAP to provide critical liver support for ...